Sarepta Therapeutics (SRPT) EBITDA Margin (2010 - 2026)
Sarepta Therapeutics' (SRPT) quarterly EBITDA Margin came in at 49.05% in Q1 2026, up 27434.0% year-on-year from N/an in Q1 2025, and up 152.78% quarter-over-quarter from 92.92% in Q4 2025.
Sarepta Therapeutics (SRPT) EBITDA Margin (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' EBITDA Margin history runs 15 years deep, the most recent figure standing at 49.05% for Q1 2026.
- On a quarterly basis, EBITDA Margin rose 27434.0% year-over-year to 49.05% in Q1 2026; TTM through Mar 2026 was 1.88%, a 535.0% increase from a year earlier, with the FY2025 full-year figure at 37.54%, down 4900.0% from the prior year.
- EBITDA Margin climbed to 49.05% in Q1 2026 per SRPT's latest filing, from 92.92% in the prior quarter.
- Across five years, EBITDA Margin topped out at 49.05% in Q1 2026 and bottomed at 225.29% in Q1 2025.
- The 5-year median for EBITDA Margin is 12.33% (2022), against an average of 33.48%.
- Across the five-year window, EBITDA Margin sank 23373 bps in 2025 and soared 27434 bps in 2026, its largest moves.
- Year by year, EBITDA Margin stood at 12.33% in 2022, then jumped by 119 bps to 2.28% in 2023, then soared by 975 bps to 24.56% in 2024, then tumbled by 478 bps to 92.92% in 2025, then jumped by 153 bps to 49.05% in 2026.
- Per Business Quant, the three latest SRPT EBITDA Margin figures stand at 49.05% (Q1 2026), 92.92% (Q4 2025), and 25.89% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Sarepta Therapeutics | 1.66 Bn | 1.25 Bn | 622.04 Mn | 49.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.05% |
| Dec 31, 2025 | -92.92% |
| Sep 30, 2025 | -25.89% |
| Jun 30, 2025 | 18.91% |
| Mar 31, 2025 | -225.29% |
| Dec 31, 2024 | 24.56% |
| Sep 30, 2024 | 4.75% |
| Jun 30, 2024 | -0.19% |
| Mar 31, 2024 | 8.44% |
| Dec 31, 2023 | 2.28% |
| Sep 30, 2023 | -6.74% |
| Jun 30, 2023 | -51.11% |
| Mar 31, 2023 | -59.65% |
| Dec 31, 2022 | -12.33% |
| Sep 30, 2022 | -57.04% |
| Jun 30, 2022 | -99.95% |
| Mar 31, 2022 | -46.02% |
| Dec 31, 2021 | -59.20% |
| Sep 30, 2021 | -153.18% |
| Jun 30, 2021 | -102.12% |